Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Faculty Opinions recommendation of Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. — Ralf Weiskirchen | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Faculty Opinions recommendation of Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
RW
Shared by
Ralf Weiskirchen
Faculty Opinions recommendation of Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
Dataset
en
Authors
RW
Ralf Weiskirchen
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Dataset
Faculty Opinions recommendation of Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.
Ralf Weiskirchen
Dataset
Faculty Opinions recommendation of Diet-Induced Rat Model of Gradual Development of Non-Alcoholic Fatty Liver Disease (NAFLD) with Lipopolysaccharides (LPS) Secretion.
Ralf Weiskirchen
DOI
10.3410/f.726760174.793547491
Year
Published
—
Language
en
Dataset Details
Link Of The Paper
https://doi.org/10.3410/f.726760174.793547491
Timeline
Created:
June 19, 2026
Article
2018
Parental non‐alcoholic fatty liver disease increases risk of non‐alcoholic fatty liver disease in offspring
Michelle T. Long
,
Ellen B. Gurary
,
Joseph M. Massaro
,
Jiantao Ma
,
Udo Hoffmann
,
Raymond T. Chung
,
Emelia Benjamin
,
Rohit Loomba
Dataset
Faculty Opinions recommendation of Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease.
Ralf Weiskirchen
Dataset
Faculty Opinions recommendation of Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review).
Ralf Weiskirchen
Discussion(0)
No comments yet. Be the first to comment.